Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	ZENG Fei [verfasserIn] LU Jie [verfasserIn] SUN Renhao [verfasserIn] FANG Yikang [verfasserIn] YU Wenyi [verfasserIn] YANG Fang [verfasserIn] ZHAO Lu [verfasserIn]

Format:	E-Artikel
Sprache:	Chinesisch

Erschienen:	2021

Schlagwörter:	head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab，

Übergeordnetes Werk:	In: 口腔疾病防治 - Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019, 29(2021), 10, Seite 706-710
Übergeordnetes Werk:	volume:29 ; year:2021 ; number:10 ; pages:706-710

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.12016/j.issn.2096-1456.2021.10.010

Katalog-ID:	DOAJ05302365X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ05302365X
003	DE-627
005	20230502140851.0
007	cr uuu---uuuuu
008	230227s2021 xx \|\|\|\|\|o 00\| \|\|chi c
024	7		\|a 10.12016/j.issn.2096-1456.2021.10.010 \|2 doi
035			\|a (DE-627)DOAJ05302365X
035			\|a (DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a chi
100	0		\|a ZENG Fei \|e verfasserin \|4 aut
245	1	0	\|a Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues.
650		4	\|a head and neck squamous cell carcinoma，
650		4	\|a programmed death receptor 1，
650		4	\|a programmed death receptor ligand 1，
650		4	\|a immunotherapy，
650		4	\|a programmed death receptor 1 inhibitor，
650		4	\|a programmed death receptor ligand 1 inhibitor，
650		4	\|a nivolumab，
650		4	\|a pembrolizumab，
650		4	\|a durvalumab，
650		4	\|a atezolizumab，
653		0	\|a Medicine
653		0	\|a R
700	0		\|a LU Jie \|e verfasserin \|4 aut
700	0		\|a SUN Renhao \|e verfasserin \|4 aut
700	0		\|a FANG Yikang \|e verfasserin \|4 aut
700	0		\|a YU Wenyi \|e verfasserin \|4 aut
700	0		\|a YANG Fang \|e verfasserin \|4 aut
700	0		\|a ZHAO Lu \|e verfasserin \|4 aut
773	0	8	\|i In \|t 口腔疾病防治 \|d Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019 \|g 29(2021), 10, Seite 706-710 \|w (DE-627)1680938088 \|x 20961456 \|7 nnns
773	1	8	\|g volume:29 \|g year:2021 \|g number:10 \|g pages:706-710
856	4	0	\|u https://doi.org/10.12016/j.issn.2096-1456.2021.10.010 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3 \|z kostenfrei
856	4	0	\|u http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2096-1456 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2096-1456 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_2817
951			\|a AR
952			\|d 29 \|j 2021 \|e 10 \|h 706-710

Indexfelder

author_variant	z f zf l j lj s r sr f y fy y w yw y f yf z l zl
matchkey_str	article:20961456:2021----::eerhrgesnrgamdetrcpo1iadihbtrnmuohrpoha
hierarchy_sort_str	2021
publishDate	2021
allfields	10.12016/j.issn.2096-1456.2021.10.010 doi (DE-627)DOAJ05302365X (DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3 DE-627 ger DE-627 rakwb chi ZENG Fei verfasserin aut Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues. head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab， Medicine R LU Jie verfasserin aut SUN Renhao verfasserin aut FANG Yikang verfasserin aut YU Wenyi verfasserin aut YANG Fang verfasserin aut ZHAO Lu verfasserin aut In 口腔疾病防治 Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019 29(2021), 10, Seite 706-710 (DE-627)1680938088 20961456 nnns volume:29 year:2021 number:10 pages:706-710 https://doi.org/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3 kostenfrei http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_2817 AR 29 2021 10 706-710
spelling	10.12016/j.issn.2096-1456.2021.10.010 doi (DE-627)DOAJ05302365X (DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3 DE-627 ger DE-627 rakwb chi ZENG Fei verfasserin aut Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues. head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab， Medicine R LU Jie verfasserin aut SUN Renhao verfasserin aut FANG Yikang verfasserin aut YU Wenyi verfasserin aut YANG Fang verfasserin aut ZHAO Lu verfasserin aut In 口腔疾病防治 Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019 29(2021), 10, Seite 706-710 (DE-627)1680938088 20961456 nnns volume:29 year:2021 number:10 pages:706-710 https://doi.org/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3 kostenfrei http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_2817 AR 29 2021 10 706-710
allfields_unstemmed	10.12016/j.issn.2096-1456.2021.10.010 doi (DE-627)DOAJ05302365X (DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3 DE-627 ger DE-627 rakwb chi ZENG Fei verfasserin aut Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues. head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab， Medicine R LU Jie verfasserin aut SUN Renhao verfasserin aut FANG Yikang verfasserin aut YU Wenyi verfasserin aut YANG Fang verfasserin aut ZHAO Lu verfasserin aut In 口腔疾病防治 Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019 29(2021), 10, Seite 706-710 (DE-627)1680938088 20961456 nnns volume:29 year:2021 number:10 pages:706-710 https://doi.org/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3 kostenfrei http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_2817 AR 29 2021 10 706-710
allfieldsGer	10.12016/j.issn.2096-1456.2021.10.010 doi (DE-627)DOAJ05302365X (DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3 DE-627 ger DE-627 rakwb chi ZENG Fei verfasserin aut Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues. head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab， Medicine R LU Jie verfasserin aut SUN Renhao verfasserin aut FANG Yikang verfasserin aut YU Wenyi verfasserin aut YANG Fang verfasserin aut ZHAO Lu verfasserin aut In 口腔疾病防治 Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019 29(2021), 10, Seite 706-710 (DE-627)1680938088 20961456 nnns volume:29 year:2021 number:10 pages:706-710 https://doi.org/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3 kostenfrei http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_2817 AR 29 2021 10 706-710
allfieldsSound	10.12016/j.issn.2096-1456.2021.10.010 doi (DE-627)DOAJ05302365X (DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3 DE-627 ger DE-627 rakwb chi ZENG Fei verfasserin aut Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues. head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab， Medicine R LU Jie verfasserin aut SUN Renhao verfasserin aut FANG Yikang verfasserin aut YU Wenyi verfasserin aut YANG Fang verfasserin aut ZHAO Lu verfasserin aut In 口腔疾病防治 Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019 29(2021), 10, Seite 706-710 (DE-627)1680938088 20961456 nnns volume:29 year:2021 number:10 pages:706-710 https://doi.org/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3 kostenfrei http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010 kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei https://doaj.org/toc/2096-1456 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_2817 AR 29 2021 10 706-710
language	Chinese
source	In 口腔疾病防治 29(2021), 10, Seite 706-710 volume:29 year:2021 number:10 pages:706-710
sourceStr	In 口腔疾病防治 29(2021), 10, Seite 706-710 volume:29 year:2021 number:10 pages:706-710
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab， Medicine R
isfreeaccess_bool	true
container_title	口腔疾病防治
authorswithroles_txt_mv	ZENG Fei @@aut@@ LU Jie @@aut@@ SUN Renhao @@aut@@ FANG Yikang @@aut@@ YU Wenyi @@aut@@ YANG Fang @@aut@@ ZHAO Lu @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	1680938088
id	DOAJ05302365X
language_de	chinesisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ05302365X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502140851.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.12016/j.issn.2096-1456.2021.10.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ05302365X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">ZENG Fei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">head and neck squamous cell carcinoma，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor 1，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor ligand 1，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor 1 inhibitor，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor ligand 1 inhibitor，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nivolumab，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pembrolizumab，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">durvalumab，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atezolizumab，</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LU Jie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SUN Renhao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">FANG Yikang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">YU Wenyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">YANG Fang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHAO Lu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">口腔疾病防治</subfield><subfield code="d">Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019</subfield><subfield code="g">29(2021), 10, Seite 706-710</subfield><subfield code="w">(DE-627)1680938088</subfield><subfield code="x">20961456</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:29</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:706-710</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.12016/j.issn.2096-1456.2021.10.010</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2096-1456</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2096-1456</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">29</subfield><subfield code="j">2021</subfield><subfield code="e">10</subfield><subfield code="h">706-710</subfield></datafield></record></collection>
author	ZENG Fei
spellingShingle	ZENG Fei misc head and neck squamous cell carcinoma， misc programmed death receptor 1， misc programmed death receptor ligand 1， misc immunotherapy， misc programmed death receptor 1 inhibitor， misc programmed death receptor ligand 1 inhibitor， misc nivolumab， misc pembrolizumab， misc durvalumab， misc atezolizumab， misc Medicine misc R Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
authorStr	ZENG Fei
ppnlink_with_tag_str_mv	@@773@@(DE-627)1680938088
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
illustrated	Not Illustrated
issn	20961456
topic_title	Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma head and neck squamous cell carcinoma， programmed death receptor 1， programmed death receptor ligand 1， immunotherapy， programmed death receptor 1 inhibitor， programmed death receptor ligand 1 inhibitor， nivolumab， pembrolizumab， durvalumab， atezolizumab，
topic	misc head and neck squamous cell carcinoma， misc programmed death receptor 1， misc programmed death receptor ligand 1， misc immunotherapy， misc programmed death receptor 1 inhibitor， misc programmed death receptor ligand 1 inhibitor， misc nivolumab， misc pembrolizumab， misc durvalumab， misc atezolizumab， misc Medicine misc R
topic_unstemmed	misc head and neck squamous cell carcinoma， misc programmed death receptor 1， misc programmed death receptor ligand 1， misc immunotherapy， misc programmed death receptor 1 inhibitor， misc programmed death receptor ligand 1 inhibitor， misc nivolumab， misc pembrolizumab， misc durvalumab， misc atezolizumab， misc Medicine misc R
topic_browse	misc head and neck squamous cell carcinoma， misc programmed death receptor 1， misc programmed death receptor ligand 1， misc immunotherapy， misc programmed death receptor 1 inhibitor， misc programmed death receptor ligand 1 inhibitor， misc nivolumab， misc pembrolizumab， misc durvalumab， misc atezolizumab， misc Medicine misc R
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	口腔疾病防治
hierarchy_parent_id	1680938088
hierarchy_top_title	口腔疾病防治
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1680938088
title	Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
ctrlnum	(DE-627)DOAJ05302365X (DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3
title_full	Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
author_sort	ZENG Fei
journal	口腔疾病防治
journalStr	口腔疾病防治
lang_code	chi
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	706
author_browse	ZENG Fei LU Jie SUN Renhao FANG Yikang YU Wenyi YANG Fang ZHAO Lu
container_volume	29
format_se	Elektronische Aufsätze
author-letter	ZENG Fei
doi_str_mv	10.12016/j.issn.2096-1456.2021.10.010
author2-role	verfasserin
title_sort	research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
title_auth	Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
abstract	Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues.
abstractGer	Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues.
abstract_unstemmed	Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ SSG-OLC-PHA GBV_ILN_11 GBV_ILN_2817
container_issue	10
title_short	Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma
url	https://doi.org/10.12016/j.issn.2096-1456.2021.10.010 https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3 http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010 https://doaj.org/toc/2096-1456
remote_bool	true
author2	LU Jie SUN Renhao FANG Yikang YU Wenyi YANG Fang ZHAO Lu
author2Str	LU Jie SUN Renhao FANG Yikang YU Wenyi YANG Fang ZHAO Lu
ppnlink	1680938088
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.12016/j.issn.2096-1456.2021.10.010
up_date	2024-07-03T15:21:56.942Z
_version_	1803571814144671744
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ05302365X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230502140851.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|chi c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.12016/j.issn.2096-1456.2021.10.010</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ05302365X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ4b84097eba984f99a944a7fbd1a0fea3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">chi</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">ZENG Fei</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor that seriously threatens human health and life. With increasing studies on the mechanism of tumor immune escape, programmed death receptor 1 (PD-1) and programmed death ligand receptor 1 (PD-L1) have been proven to be involved in tumor immune escape. The primary mechanism is that PD-1 recruits protein tyrosine phosphatase (SHP-2) to dephosphorylate downstream tyrosine kinase (SyK) and phosphatidylinositol 3-kinase (PI3K), thereby inhibiting downstream protein kinase B (AKT), extracellular regulated protein kinases (ERK) and other important signaling pathways, ultimately inhibiting T cell activation. In recent years, PD-1/PD-L1 inhibitors have become popular immunotherapies. Pembrolizumab and nivolumab have been approved for HNSCC patients by the U.S. Food and Drug Administration. Both durvalumab and atezolizumab are still in clinical trials, and published data show that both have certain safety and efficacy but still need much clinical data to support them. Meanwhile, the combination of PD-1/PD-L1 inhibitors with radiotherapy, chemotherapy and immunotherapy is still controversial in terms of clinical efficacy and adverse events, and further research is needed. However, serious immune-related adverse reactions limit the clinical application of PD-1/PD-L1 inhibitors, despite promising curative effects. Therefore, developing novel inhibitors and investigating stable and effective biomarkers and upstream and downstream signaling mechanisms are urgent issues.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">head and neck squamous cell carcinoma，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor 1，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor ligand 1，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunotherapy，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor 1 inhibitor，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">programmed death receptor ligand 1 inhibitor，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">nivolumab，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pembrolizumab，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">durvalumab，</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">atezolizumab，</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">LU Jie</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">SUN Renhao</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">FANG Yikang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">YU Wenyi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">YANG Fang</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">ZHAO Lu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">口腔疾病防治</subfield><subfield code="d">Editorial Department of Journal of Prevention and Treatment for Stomatological Diseases, 2019</subfield><subfield code="g">29(2021), 10, Seite 706-710</subfield><subfield code="w">(DE-627)1680938088</subfield><subfield code="x">20961456</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:29</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:10</subfield><subfield code="g">pages:706-710</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.12016/j.issn.2096-1456.2021.10.010</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/4b84097eba984f99a944a7fbd1a0fea3</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.kqjbfz.com/CN/10.12016/j.issn.2096-1456.2021.10.010</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2096-1456</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2096-1456</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2817</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">29</subfield><subfield code="j">2021</subfield><subfield code="e">10</subfield><subfield code="h">706-710</subfield></datafield></record></collection>
score	7.40108

Nicht das Richtige dabei?

Schreiben Sie uns!

Research progress on programmed death receptor 1/ ligand 1 inhibitor in immunotherapy of head and neck squamous cell carcinoma

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?